Jan Skvarka's Insider Trades & SAST Disclosures

Jan Skvarka's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 60,000 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on Jan. 31, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Zentalis Pharmaceuticals Inc
Jan Skvarka Director Purchase of securities on an exchange or from another person at price $ 1.72 per share. 31 Jan 2025 60,000 149,551 - 1.7 103,446 Common Stock
Zentalis Pharmaceuticals Inc
Jan Skvarka Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Jun 2024 41,581 89,551 - 0 Common Stock
Monte Rosa Therapeutics Inc
Jan Skvarka Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Jun 2024 22,100 22,100 - - Stock Option (Right to Buy)
Zentalis Pharmaceuticals Inc
Jan Skvarka Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2023 16,364 52,970 - 0 Common Stock
Monte Rosa Therapeutics Inc
Jan Skvarka Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Jun 2023 20,500 20,500 - - Stock Option (Right to Buy)
Monte Rosa Therapeutics Inc
Jan Skvarka Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Mar 2023 41,000 41,000 - - Stock Option (Right to Buy)
Zentalis Pharmaceuticals Inc
Jan Skvarka Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Sep 2022 36,606 36,606 - 0 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades